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mice are born with very long telomeres—
much longer than human telomeres—
mouse telomeres do suffer extensive
shortening associated with aging (Flores
et al., 2008). Inparticular,whilemousecells
maintain relatively long telomeres during
their first year of life, there is a dramatic
loss of telomeric sequences at 2 years of
age, even in various stem cell populations,
and this change is concomitant with the
loss of regenerative capacity associated
with mouse aging. In addition, telome-
rase-deficient mice from the first genera-
tion (G1Terc/) exhibit a significant
decrease in median and maximum
longevity and a higher incidence of age-
related pathologies and stem cell dysfunc-
tion compared with wild-type mice (Flores
et al., 2005; Garcia-Cao et al., 2006), indi-
cating that, as in humans, telomerase
activity is rate limiting for natural mouse
longevity and aging. These results suggest
that strategies aimed to increase telome-
rase activity may delay natural mouse
aging. Further supporting this notion, it
was recently shown that overexpression
of TERT in the context of mice engineered
to be cancer resistant owe to increase
expression of tumor suppressor genes
(Sp53/Sp16/SARF/TgTERT mice) was
sufficient to decrease telomere damage
with age, delay aging, and increasemedian
longevity by 40% (Tomas-Loba et al.,
2008). However, it remains to be seen
whether telomerase reactivation late in life
would be sufficient to delay natural mouse
aging and extend mouse longevity without
increasing cancer incidence.
In summary, these proof-of-principle
studies using genetically modified mice
are likely to encourage the development
of targeted therapeutic strategies based
on reactivation of telomerase function.
Indeed, small molecule telomerase acti-
vators have been reported recently and
have demonstrated some preliminary
health-span beneficial effects in humans
(Harley et al., 2010). Identifying drugable
targets and candidate activators clearly
opens a new window for the treatment of
age-associated degenerative diseases.
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In this issue of Cell Stem Cell, Zhang et al. (2011) generate patient-derived iPSCs for one of the major prema-
ture aging diseases, Hutchinson-Gilford Progeria Syndrome (HGPS). These cells are amuch-needed new tool
to study HGPS, and their use may lead to novel insights into mechanisms of aging.Some problems in biology are more
difficult to study than others. Human
aging is certainly one of them. Most
conclusions regarding molecular mecha-
nism of human aging rely onmere correla-
tion, and direct experimental testing
is generally not feasible. One approach
to dissect the molecular basis of human
aging is to study naturally occurring
premature aging disorders. One of the
most dramatic and prominent of such4 Cell Stem Cell 8, January 7, 2011 ª2011 Eldiseases is Hutchinson-Gilford Progeria
Syndrome (HGPS). Zhang et al. (2011)
now report the generation of induced
pluripotent stem cells (iPSCs) from
HGPS cells, providing a powerful new
tool to unravel the molecular and physio-
logical mechanisms of premature and
normal aging.
HGPS is a truly remarkable disease in
many ways. To start with, it affects an
unusually wide spectrum of tissues andsevier Inc.leads to the development of highly diverse
symptoms ranging from depletion of
subcutaneous fat to loss of hair and
tendon contractures. The diversity of
affected tissues pointed early on to stem
cell defects as a likely disease mecha-
nism. Most relevant in patients are
vascular defects and recurring strokes,
which invariably are fatal in patients in
their mid- to late teens (Hennekam,
2006). The disease is exceedingly rare
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at any time, making access to relevant
tissues very difficult. HGPS is also re-
markable in how much we know about
its molecular and cellular basis. HGPS is
caused by a mutation in the LMNA gene
encoding the intermediate filament
proteins lamin A and C, key architectural
components of the cell nucleus and both
involved in higher-order genome organi-
zation (Worman et al., 2010). The disease
mutation leads to activation of a cryptic
splice site in LMNA and the production
of a dominant gain-of-function isoform of
lamin A, referred to as progerin. This
protein is permanently farnesylated at its
C terminus and accumulates in the
nuclear lamina, where it disrupts normal
lamina function.
Progerin is not only relevant to HGPS,
but also to normal aging, because the
cryptic splice site which creates progerin
is also used at low frequency in healthy
individuals and progerin can be found in
normal tissues (Scaffidi and Misteli,
2006). Further parallels between HGPS
and normal aging are suggested, given
that several cellular defects such as loss
of epigenetic marks and increased DNA
damage are observed in both settings. In
addition, HGPS patients and normally
aged individuals exhibit similar vascular
defects. Due to the rarity of the disease
and the fragility of the patients it is diffi-
cult, however, to obtain relevant biolog-
ical materials for molecular analysis,
and much of what we know about the
disease’s mechanisms comes from cul-
tured skin cells and animal models. The
generation of HGPS-derived iPSCs now
reported by Zhang et al. (2011) now
provides a much needed source for
tissue-specific cell lines with which to
probe the effect of progerin on tissue
function and differentiation.
The HGPS-derived iPSCs were gener-
ated from patient skin fibroblasts using
the standard Yamanaka method (Zhang
et al., 2011). The derived cells appeared
pluripotent since they form teratomas
and exhibit gene expression profiles akin
to established human embryonic stem
cell (hESC) lines. Interestingly, though,
the efficiency of iPSC generation from
HGPS patient cells was lower than from
wild-type control cells. This might be
due, as the authors suggest, to early
onset of senescence in HGPS cells, but
it might also have something to do withan inhibitory role of progerin on the
large-scale chromatin reorganization
required during reprogramming. We
know that lamins tether chromatin to the
periphery and clamp it down into hetero-
chromatin and that progerin solidifies the
normally dynamic nuclear lamina (Dahl
et al., 2006). ESCs are one of few human
cell types that do not express lamins
A and C, and at the same time, they lack
heterochromatin, possibly as a means to
maintain broad genome plasticity. It is
conceivable that the presence of progerin
in HGPS cells prevents the dynamic
reorganization of chromatin required for
efficient reprogramming.
The derivation of HGPS-iPSCs is of
significant practical importance. The
described cells are able to differentiate
into five lineages, including vascular
smooth muscle cells (VSMCs) and
mesenchymal stem cells (MSCs) (Zhang
et al., 2011), confirming their multipo-
tency. These cells now offer a useful
experimental system to probe the effect
of progerin on the differentiation of
various cell lineages, something that
could not be done before because of the
inability to obtain tissue samples from
patients. These cells also open the door
to performing critical experiments, such
as transplantation of HGPS-derived
MSCs into the vasculature of animal
models to probe the physiological mech-
anisms that participate in the vascular
defects experienced by HGPS patients.
The HGPS-iPSCs, and their derivatives,
will also be useful for drug discovery. At
present, the only clinical strategy for
HGPS is farnesyltransferase inhibitors
(FTIs), which prevent the addition of the
C-terminal farnesyl group on progerin
(Capell and Collins, 2006). While FTIs
have been shown to reverse cellular
phenotypes and have a positive effect
on vasculature and on extension of life-
span in animal models, the nonspecific
nature of the drug might become limiting
in clinical applications. Lineage-differenti-
ated cell lines derived from HGPS-iPSCs
will provide ample and well-controlled
biological materials for the search of novel
drugs in high-throughput screens.
Although the HGPS-derived iPSCs
appear to differentiate normally in vitro,
they are functionally compromised, pro-
viding some insights into disease mecha-
nism (Zhang et al., 2011). HGPS-iPSC-
derived cells are hypersensitive to variousCell Stem Cforms of stress. Survival of HGPS-iPSC-
derived VSMCs was significantly reduced
under hypoxic conditions or when sub-
jected to extended electrical stimulation.
The latter is potentially relevant to their
pathological function because VSMCs
undergo extensive mechanical stress
in vivo due to the pulsing of the vascula-
ture, and the reduced survival and prolif-
eration observed in vitro may suggest
increased cell death in the vasculature
of HGPS patients. HGPS-iPSC-derived
MSCs were also functionally compro-
mised in vivo. When transplanted into an
ischemic hind-limb muscle, they were
unable to prevent necrosis, whereas
MSCs derived in parallel from control
iPSCs did. This failure may be due to the
inability of HGPS-derived MSCs to
replace vascular cells that are removed
due to their normal turnover and/or the
poor survival of these cells in the hypoxic
environment of the muscle. Although it
remains unclear why exactly the HGPS-
iPSC-derived MSCs failed to rescue
these defects, it is tempting to consider
that MSC transplantation may offer a
novel therapeutic option for HGPS. An
intriguing, albeit distant, goal may be the
generation of patient-derived MSCs in
which the LMNA mutation has been
corrected using recombination-based
approaches.
These observations onmuscle regener-
ation are also directly relevant to our
thinking about normal aging. Loss of
regeneration capacity has become a pre-
vailing, albeit quite obvious, model for
aging (Sharpless and DePinho, 2007). If
tissue cells, and particularly stem cells,
which are lost from a tissue due to normal
turnover, are not replaced efficiently,
tissues will, of course, deteriorate. It ap-
pears that in the case of HGPS, and likely
in normal aging, tissue stem cells become
increasingly unable to keep upwith regen-
eration of lost tissue cells. This pattern
may arise for several reasons. Tissue
stem cell numbers may be reduced due
to increased apoptosis, in the case of
HGPS possibly due to their inability to
cope with stress, for example, under
hypoxic conditions in tissues. In addition,
tissue stem cells might fail to self-renew,
or they may produce fewer and function-
ally impaired offspring. TheHGPS-derived
iPSCs should be useful in further resolving
the relevanceof thesevariouspathways to
organismal aging.ell 8, January 7, 2011 ª2011 Elsevier Inc. 5
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PreviewsHGPS is an extraordinary disease,
and the generation of patient-derived
iPSCs is a significant milestone. This
step continues the remarkable progress
made in the last few years. After discovery
of the disease-causing gene in 2003, it
only took four years to initiate several
clinical trials. Much has been learnt along
the way about the biology of HGPS and its
relevance to normal aging. The generation
of iPSCs fromHGPS patients now heralds
another wave of rapid progress withA Roundabout Wa
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A new player in hematopoietic stem
Smith-Berdan et al. (2010) demonstr
so in cooperation with Cxcr4 to gui
Bone marrow (BM) transplantation has
been used for treatment of hematopoietic
disorders for some fifty years and repre-
sents a paradigm for all future stem cell
therapies. A number of cytokines, espe-
ciallygranulocytecolony-stimulating factor
(G-CSF), are known to mobilize hemato-
poietic stem and progenitor cells (HSPCs)
from their BM niches into the peripheral
blood (PB) (Papayannopoulou and Scad-
den, 2008). Indeed, mobilization is the
preferred method for obtaining transplant-
able HSC. Despite the number of currently
available HSPC mobilizing agents, a
significant number of donors mobilize
poorly. Therefore, identifying novel and
more efficient mobilization approaches is
of paramount clinical importance.
Understanding the molecular frame-
work of how the niche regulates retention
and release of stem cells provides the
ground onwhich to base alternativemobi-
lization strategies. The basic processes of
transplantation are homing to, engraft-
ment in, and retention of HSCs in the
niche. Mobilization may thus be under-
6 Cell Stem Cell 8, January 7, 2011 ª2011 Eimplications for HGPS disease mecha-
nisms, for aging in general, and potentially
as a tool to develop novel strategies to
combat vascular disease.
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cell (HSC)-niche interactions is introd
ate that Robo4 is involved in HSC eng
de stem cells to and secure them in
stood as the process of breaking the
bonds of stem cell retention in the BM
niche or enhancement of the existing
means that allow HSCs to enter the PB.
The cellular milieu and molecular mecha-
nisms that mediate these processes are
starting to be revealed but, at best, remain
poorly understood (Garrett and Emerson,
2009). The Cxcr4/Cxcl12 axis has been
identified as critically important in homing,
engraftment, and retention in theBM (Lap-
idot et al., 2005). Previouswork has shown
that the Cxcr4 antagonist AMD3100 can
mobilize both mouse and human HSPCs
and has found use clinically as an adjunct
therapy for poor G-CSF mobilizers (Brox-
meyer et al., 2005). In this issue of Cell
Stem Cell, Smith-Berdan et al. show that
Roundabout 4 (Robo4), a neuronal guid-
ance molecule, regulates engraftment
and mobilization and, in cooperation with
Cxcr4, localizes HSCs to the niche.
Previous profiling studies by the senior
author had revealed that Robo4 was ex-
pressed at high levels in long-term HSCs
(Forsberg et al., 2005). In the present
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raftment andmobilization and does
the niche.
work, the authors show that Robo4
becomes downregulated upon differenti-
ation, consistent with the observations of
Shibata et al., who also demonstrated
that repopulating cells segregated to the
Robo4+ fraction of HSPCs (Shibata et al.,
2009). Notably, Smith-Berdan et al. also
found that Robo4 expressionwas dramat-
ically downregulated in mobilized HSCs.
To determine a functional role for Robo4
in HSCs, the authors investigated Robo4
knockout mice. Robo4/ mice appear
normal but have defects in vascular integ-
rity and angiogenesis (Jones et al., 2008).
An analysis of the stem cell compartments
revealed that Robo4/ mice had a spe-
cific decrease of HSCs in the BM with a
reciprocal increase in PB, suggesting
poor BM retention. Upon transplantation,
Robo4/ HSCs engrafted poorly, but
those that did engraft contributed to a
normal spectrum of blood cell lineages.
In addition, the ability of Robo4/ HSC
tomake spleen colonies was normal, sug-
gesting that the engraftment defect was
likely because of a specific impairment of
